First-line treatment and overall survival in EGFR mutation-positive advanced non-small cell lung cancer: a national cohort study

Huang LY, Chang HP, Chang RY, Tai HY, Huang YW, Lee PC
Record ID 32018004183
Authors' objectives: Non-squamous non-small cell lung cancer (NSCLC) is the first leading cause of cancer-related deaths in Taiwan. This study aimed at evaluating the effectiveness of first-line targeted therapy for advanced epidermal growth factor receptor (EGFR) mutation-positive non-squamous NSCLC in Taiwan.
Authors' results and conclusions: These data represent the potential survival outcomes of Taiwanese patients with advanced EGFR mutation-positive non-squamous NSCLC in clinical practice.
Authors' recommendations: Our study analyzed big data from the NHI database over the last 20 years. We found that the survival rate in Group 1 (received first-line targeted drugs from 2011 to 2019) was significantly higher than that of the control group (2002-2010 chemotherapy, Group 3).
Authors' methods: This was a real-world, retrospective, observational study of patients diagnosed with advanced non-squamous NSCLC (N=63,248). Between 2011 and 2019, 19,458 patients received targeted therapy and 22,994 patients received chemotherapy alone; between 2002 and 2010, 20,796 patients received chemotherapy alone. Overall survival (OS) was determined.
Project Status: Completed
Year Published: 2022
English language abstract: An English language summary is available
Publication Type: Full HTA
Pubmed ID: 36314347
MeSH Terms
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • ErbB Receptors
  • Protein Kinase Inhibitors
Organisation Name: Center for Drug Evaluation
Contact Address: 3F.,No.465, Sec.6, Zhongxiao E. Rd., Taipei 11557, Taiwan. R.O.C.
Contact Name: Li Ying (Grace) Huang
Contact Email:
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.